Acute myeloid leukaemia with myelodysplasia-related features

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86845OMIM:601626C92.8
Who is this for?
Show terms as
2FDA treatments2Active trials26Specialists8Treatment centers1Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

AML with multilineage dysplasiaAcute myeloid leukemia with multilineage dysplasiaAML with myelodysplasia-related features
Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

2 events
Aug 2022Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI) — PHASE2

TrialACTIVE NOT RECRUITING
Sep 2010Characterization of the Mechanisms of Resistance to Azacitidine

Centre Hospitalier Universitaire de Nice

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

VYXEOS

Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection· Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)

treatment of newly-diagnosed AML with myelodysplasia-related changes (AML-MRC)

View Details →FDA Label ↗Copay Card ↗Patient Assistance ↗

Rydapt

RYDAPT· Novartis Pharmaceuticals Corporation
indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia …

indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by an FDA approved test

View Details →FDA Label ↗

Clinical Trials

2 recruitingView all trials with filters →
Phase 21 trial
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
Phase 2
Active
PI: Joshua F Zeidner (Ohio State University Comprehensive Cancer Center ) · Sites: Atlanta, Georgia; Kansas City, Kansas +9 more · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other1 trial
Characterization of the Mechanisms of Resistance to Azacitidine
Actively Recruiting
· Sites: Antibes; Nice +2 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 26View all specialists →
JZ
Joshua F Zeidner
CHAPEL HILL, NC
Specialist
PI on 1 active trial
JF
James Foran
JACKSONVILLE, FL
Specialist
PI on 1 active trial
SM
Sanjay Mohan, MD
NEW YORK, NY
Specialist
PI on 3 active trials
BS
Brenda Sandmaier
SEATTLE, WA
Specialist
PI on 17 active trials
BS
B. Smith
OKLAHOMA CITY, OK
Specialist
PI on 6 active trials
JK
Judith Karp
BALTIMORE, MD
Specialist
PI on 9 active trials
RW
Roland Walter
SEATTLE, WA
Specialist
PI on 9 active trials
BS
Bart Scott
SEATTLE, WA
Specialist
PI on 3 active trials
CD
Courtney DiNardo
HOUSTON, TX
Specialist
PI on 3 active trials
SG
Steven Gore
Specialist
PI on 2 active trials
CD
Colleen Delaney
OLD GREENWICH, CT
Specialist
PI on 3 active trials
GG
Guillermo Garcia-Manero
HOUSTON, TX
Specialist
PI on 9 active trials
BM
Brenda Cooper, MD
Specialist
PI on 3 active trials
MM
Michael Savona, MD
NASHVILLE, TN
Specialist
PI on 4 active trials
MK
Mark Kirschbaum
HERSHEY, PA
Specialist
PI on 4 active trials2 Acute myeloid leukaemia with myelodysplasia-related features publications
GC
George Chen
Specialist
PI on 2 active trials
MJ
Mark Juckett
MINNEAPOLIS, MN
Specialist
PI on 3 active trials
JP
John Pagel
SEATTLE, WA
Specialist
PI on 4 active trials
NM
Nathalie Douet-Guilbert, MD,PhD
Specialist
PI on 1 active trial
JD
John Deeken
FAIRFAX, VA
Specialist
PI on 1 active trial
RP
Roland Walter, MD, PhD
SEATTLE, WA
Specialist
PI on 2 active trials
AM
Alison Walker, MD
Specialist
PI on 3 active trials
JM
Joseph Rosenthal, MD
Specialist
PI on 3 active trials
DI
David J Iberri
STANFORD, CA
Specialist
PI on 1 active trial
EG
Eva Guinan
BOSTON, MA
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
VYXEOS(Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection)— Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)

Travel Grants

No travel grants are currently matched to Acute myeloid leukaemia with myelodysplasia-related features.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Acute myeloid leukaemia with myelodysplasia-related featuresForum →

No community posts yet. Be the first to share your experience with Acute myeloid leukaemia with myelodysplasia-related features.

Start the conversation →

Latest news about Acute myeloid leukaemia with myelodysplasia-related features

Disease timeline:

New recruiting trial: Characterization of the Mechanisms of Resistance to Azacitidine

A new clinical trial is recruiting patients for Acute myeloid leukaemia with myelodysplasia-related features

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Acute myeloid leukaemia with myelodysplasia-related features

Are there clinical trials for Acute myeloid leukaemia with myelodysplasia-related features?

Yes — 2 recruiting clinical trials are currently listed for Acute myeloid leukaemia with myelodysplasia-related features on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Acute myeloid leukaemia with myelodysplasia-related features?

25 specialists and care centers treating Acute myeloid leukaemia with myelodysplasia-related features are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Acute myeloid leukaemia with myelodysplasia-related features?

1 patient support program are currently tracked on UniteRare for Acute myeloid leukaemia with myelodysplasia-related features. See the treatments and support programs sections for copay assistance, eligibility, and contact details.